With a lack of new blockbuster drugs in the pipeline, the global pharmaceutical industry is increasingly under financial pressure. A report released in December last year by the US Government Accountability Office (http:// www.gao.gov/new.items/d0749.pdf) states that between 1993 and 2004 annual research and development spending by the pharmaceutical industry increased 147% to nearly $40 billion. Yet during this period, the number of new drug applications to the US Food and Drug Administration grew by only 38%, and discouragingly, nearly two-thirds of the new applications were for drugs that were modifications of existing medicines with only one-third for innovative new drugs. Such financial pressures may explain in part why big pharma is rushing to set up collaborations with local companies in cost-effective locations like India. In addition to a significant pool of trained biomedical and chemistry professionals and a strong bioinformatics tradition, India has a large genetically diverse population from which to recruit patients for clinical trials.
Forging New Alliances
The recent rush of big pharma to India has been dramatic (see Table 1 ). For example, in January 2006, Wyeth Pharmaceuticals based in New Jersey, which does not usually outsource drug discovery, signed a five-year contract to collaborate on medicinal chemistry projects with GVK Biosciences in Hyderabad. Then in August last year, the US pharmaceutical giant Eli Lilly, based in Indianapolis, began forging a series of new alliances with Indian companies. First came a collaboration with Hyderabad-based Suven Life Sciences for preclinical research and development of molecules targeting G protein-coupled receptors for the treatment of central nervous system disorders. Next came a multiyear deal with the largest Indian software company Tata Consultancy Services (TCS) to advance Lilly's clinical research and development through statistical analysis and management of clinical data. The TCS-Lilly deal is considered unique because clinical data is so valuable to drug companies that its management is rarely outsourced. "We have crossed the psychological barrier as it's the first time that statistical analysis is being outsourced" says Mathukumalli Vidyasagar, Executive Vice President (Advanced Technology) of TCS, who also supervises life sciences research at TCS. Finally, on January 12 th this year, Eli Lilly announced yet another new drug development agreement with the Mumbai-based company Nicholas Piramal India Ltd. Under this agreement, the Indian company will develop and commercialize some of Lilly's newer drug candidates for treating metabolic disorders. "The first candidate has already been patented by Lilly and brought to the preclinical stage. We will take it further till phase II, after which Lilly has a call back option to take it further into phase III," says Dr. Swati Piramal, director of strategic alliances and communications at NPIL. Both companies share the risk and reward. "The agreement envisages a number of molecules going through this 'relay race' idea of partnership," says Piramal, a medical doctor turned entrepreneur.
Other big pharma players with existing connections in India like Pfizer, Novartis, GlaxoSmithKline (GSK), and AstraZeneca have all announced investments to ramp up activities for drug discovery and clinical research at their existing Indian centers. Even Merck, one of the few global drug companies without a research center in India, announced in November last year a partnership with Advinus Therapeutics, a company based in Pune and Bangalore. The deal is potentially worth $150 million for Advinus in the form of milestone payments when certain benchmarks are reached. Initially, Advinus will convert drug targets for metabolic disorders identified by Merck into experimental drugs and will conduct early clinical trials, which will be taken further if found promising. In addition, on commercialization, Advinus will be paid royalties.
Meanwhile, Amgen, a major US biotechnology company based in California, formed a local affiliate in Mumbai in December 2006 to conduct clinical trials in India. The initial activities of this center will focus "primarily on enrolling and conducting clinical trials for several Amgen investigational products," said Kevin Stark, senior director R&D Strategic Operations. Amgen is also looking to collaborate with Indian academic research institutes as well as other Indian drug companies. ALTANA Pharma AG, based in Konstanz, Germany, set up a research center in Mumbai last year to recruit "tens of thousands of chemists that graduate from Indian universities every year," says Felix Reutter, director of chemical research at ALTANA's subsidiary in Mumbai. Low salary costs are of course an advantage, although Reutter feels that this will "diminish in the future."
Indian Pharma Enters the Global Arena
Although known as a major supplier of generic drugs, India has begun to forge new alliances with big US and European pharma companies. Such collaborations are helping to shepherd Indian drug companies into a new era of innovative drug discovery, but regulations governing patents, drug approvals, and clinical trials are still in the process of being updated.
Restructuring Old Laws
But it is not only financial pressures that are driving big pharma and biotech companies to India. The recent restructuring of both a 1970 Patent Law and the Indian Drugs and Cosmetics Act of 1940 has made India attractive for drug discovery. In 2005, India adopted a new patent regime that is in compliance with Trade Related Intellectual Property Rights under the World Trade Organization agreement. Prior to 2005, India only granted drug companies 'process patents,' which protect the chemical processes for production of the drug but not the drug itself. This enabled Indian drug companies to use modified processes or "reverse engineering" to produce generic versions of branded drugs. Under the new law, India now allows the granting of "product patents," which protect the final drug product and are recognized worldwide. This new law means that henceforth Indian companies cannot produce knockoff drugs free of the cost of R&D and so will be compelled to have a pipeline of innovative drugs of their own.
"This improvement in the patent law has led the global pharma to flock to India. These companies had always been looking to utilize the intellectual talent but were not sure if their intellectual property would be protected," says John Morris, London-based global head of chemicals and pharmaceuticals at the consulting firm KPMG. For the last 25 years, the existence of process patents led many multinationals to abandon the subcontinent, allowing India to become a leading producer of generic drugs, accounting for 22% of the global generics market including the antiretroviral drugs used for treating AIDS. A new KPMG report notes that the past 24 months have seen multinationals flock back to India. According to this report, the Indian pharma industry currently represents just $6 billion of the global $550 billion pharmaceutical industry but is growing at 10% annually (the global industry growth rate is 7% The new alliances between big pharma and Indian drug companies are expected to go a long way in transforming India's role in drug discovery and may change the way multinationals partner with companies in other Asian countries. Both the Lilly and Wyeth agreements require that TCS and GVK, respectively, set up dedicated facilities that will work exclusively on foreign partner projects. Clearly, these alliances depend on close collaborations but it is too early to say which way such collaborations will go. "I do not see any evidence of serious discovery research partnership," cautions Vijay Chandru, scientist-turned-entrepreneur and cofounder and CEO of Strand Life Sciences in Bangalore, which offers varied consultancy services, scientific computational tools, and chemical modeling expertise. "The recent deals announced by Merck, Lilly, and Wyeth need to be examined closely. If the rewards are loaded around milestones, with no serious up front payments, then it is not genuine partnership as there is no risk sharing," says Chandru.
Indian researchers also worry that these new drug discovery research and development efforts may cause a human resource crunch. India certainly has the talent to accept the increase in pharmaceutical research challenges. However, points out Mukund K. Gurjar, a synthetic chemist at the National Chemical Laboratory (NCL) in Pune, "unfortunately our present educational system does not provide the workforce to participate or lead the drug discovery and development programs and, therefore, per-haps the leadership in pharma R&D in India mostly comes from abroad." Vidyasagar agrees. He thinks the much talked about skill shortage in the Indian information technology (IT) industry will pale in comparison to the life sciences sector. "You can take a reasonably well-educated person and turn him into a fairly decent IT professional in 12 months, but it cannot be done in medicinal chemistry or life sciences," he says, noting that these fields could witness an acute shortage of skilled people.
Traditionally, the focus of global pharma outsourcing to India was in the manufacture of intermediates. However, Govindrajan Padmanaban, former director of the Indian Institute of Science in Bangalore and a Distinguished Biotechnologist of the federal Department of Biotechnology, points out that "our biology has improved and we have become reasonably good at target identification and validation where India's bioinformatics expertise has come to play a significant role." But he concedes that Indian industry and academia still lack expertise to design and develop new molecules, which is where alliances with big pharma become necessary. Gurjar points out that uniting with big pharma also helps to solve the problems that Indian drug companies face when trying to take new molecules to the trial stage. Big pharma provides money for trials, deals with regulatory authorities, and provides research data; and the local companies recruit patients and run the trials following big pharma's protocols.
There are already a number of clinical trials underway in India. Pfizer, which is the first multinational to establish clinical research operations in India, is conducting phase II to phase IV studies in India for new drugs to treat respiratory, cardiovascular, and metabolic diseases as well as breast cancer. GSK is testing drugs for treating schizophrenia and cancer of the head and neck, and its cervical cancer vaccine Cervarix is also currently being tested in India. Wyeth has recently announced agreements with Jahangir Hospital in Pune and Tata Memorial Hospital in Mumbai for long-term associations in clinical trials. Tarrytown, New Yorkbased Emisphere Technologies concluded its multicenter phase II study of oral insulin in October last year, which was coordinated by Mumbaibased contract research organization iGate Clinical Research.
Monitoring Clinical Trials
India has been luring the global drug industry to its shores partly because of business prospects and partly with an eye on improving its own healthcare infrastructure. However, its newly amended patent and drug policies do not match its capabilities for enforcing these new regulations. "India has absolutely no capability for enforcement. I have not heard of any blacklisted drug company, research institution or medical doctor," says Falguni Sen, professor of manage- Equally important is the vulnerability of Indian patients enrolled in clinical trials, most of whom lack state health insurance. Poor patients see clinical trials as a way to get temporary healthcare, but as there are no legislation or even guidelines in India requiring drug companies to provide the medication after the drug gets approved and sold in India, such patients can be left in the lurch. "Unlike the West, patients in India are not insured. New Delhi, therefore, needs to devise some mechanism, maybe some subsidy to insurance companies, under which patients get insurance both during and after the trial," suggests Sen. "In the West, this is not an issue. If the human subject is insured, then the new drug automatically comes under insurance but in India there is no post-trial care," he says.
The introduction of new patent laws and drug regulations in India and the transition of local Indian drug companies to global partners with big pharma has been relatively smooth so far. However, the impact of these many rapid changes on the ability of Indian companies to retain their philosophy of supplying cheap drugs to the developing world and the effects of these changes on clinical trials conducted in India remain to be seen.
